Valuation: Sareum Holdings plc

Capitalization 29.79M 40.27M 34.39M 31.51M 55.17M 3.85B 55.45M 375M 146M 1.83B 151M 148M 6.36B P/E ratio 2026 *
-
P/E ratio 2027 * -
Enterprise value 28.79M 38.92M 33.24M 30.45M 53.31M 3.72B 53.59M 363M 141M 1.77B 146M 143M 6.14B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.15%
Yield 2026 *
-
Yield 2027 * -
1 week+7.50%
Current month+4.88%
1 month+16.22%
3 months+19.44%
6 months+53.57%
Current year+43.33%
1 week 19
Extreme 19
22
1 month 18.5
Extreme 18.5
23
Current year 13
Extreme 13
23
1 year 9.5
Extreme 9.5
29
3 years 9.5
Extreme 9.5
142
5 years 9.5
Extreme 9.5
500
10 years 9.5
Extreme 9.5
500
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 58 2003-07-31
Chief Executive Officer 65 2003-07-31
Corporate Secretary 72 2018-11-12
Director TitleAgeSince
Director/Board Member 65 2010-11-10
Director/Board Member 58 2010-11-10
Chairman 67 2016-05-16
Change 5d. change 1-year change 3-years change Capi.($)
0.00%+7.50%+30.30%-82.80% 40.27M
+0.12%+2.50%+44.14%+83.32% 50.04B
-1.28%-0.07%+81.96%+64.48% 48.62B
+1.72%-13.93%+79.56%+529.95% 25.57B
-1.53%-3.18%-2.40%-12.36% 23.32B
-3.84%-2.16%+36.81%-29.60% 17.89B
-1.66%-4.83%+32.60%-41.30% 16.2B
-2.99%-10.44%+50.79%+194.05% 14.97B
-0.84%+5.27%-23.65%+992.44% 14.58B
-4.20%-4.75%+38.38% - 13.47B
Average -1.45%-1.50%+36.85%+188.69% 22.47B
Weighted average by Cap. -1.14%-2.61%+45.80%+173.95%

Financials

2026 *2027 *
Net sales - -
Net income - -
Net Debt -1M -1.35M -1.15M -1.06M -1.85M -129M -1.86M -12.59M -4.9M -61.39M -5.07M -4.97M -213M -
Logo Sareum Holdings plc
Sareum Holdings plc is a United Kingdom-based clinical-stage biotechnology company. The principal activity of the Company is the discovery and development of new therapeutic drugs using a combination of skills in biology, computational chemistry and medicinal chemistry. The Company is focused on advancing inhibitors of the JAK kinase family into clinical development for autoimmune disease and cancer. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, including psoriasis, and has completed Phase 1 clinical development. The Company is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. Additionally, the Company owns the license for SRA737, a clinical-stage oral, selective Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Employees
5
Date Price Change Volume
26-05-14 21.50 p 0.00% 22,958
26-05-13 21.50 p 0.00% 122,073
26-05-12 21.50 p 0.00% 164,923
26-05-11 21.50 p +7.50% 658,222
26-05-08 20.00 p 0.00% 31,567
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2150GBP
Average target price
0.4160GBP
Spread / Average Target
+93.49%

Annual profits - Rate of surprise